Skip to main content
Top
Published in: Tumor Biology 3/2015

01-03-2015 | Research Article

Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET

Authors: Chengjun Sui, Feng Xu, Weifeng Shen, Li Geng, Feng Xie, Binghua Dai, Jiongjiong Lu, Minfeng Zhang, Jiamei Yang

Published in: Tumor Biology | Issue 3/2015

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world with poor prognosis. Here, we investigated the role of microRNA 218 (miR-218) in regulating human HCC development. Quantitative PCR (qPCR) was used to compare the expression levels of miR-218 between eight HCC and a normal liver cell lines, as well as nine primary HCC tissues and adjacent non-carcinoma tissues. HCC cell lines MHCC97L and Huh7 were transfected with lentiviral vector of miR-218 mimics. The effect of miR-218 overexpression on cancer cell growth, both in vitro and in vivo, as well as cancer cell invasion was examined. A bioinformatic method was used to predict the binding of miR-218 to RET proto-oncogene (RET). Small interfering RNA (SiRNA)-mediated genetic knock-down of RET was performed in MHCC97L and Huh7 cells, and its modulatory effect on miR-218-mediated HCC development was examined. miR-218 was found to be downregulated in HCC cell lines and primary HCC tissues. Overexpression of miR-218 in MHCC97L or Huh7 cells resulted in significant decrease in cell proliferation and invasion capability. Overexpression of miR-218 also reduced the tumor growth of xenografted Huh7 cells in vivo. The expression of endogenous RET was found to be upregulated by miR-218, and siRNA-induced RET downregulation resulted in phosphatase and tensin homolog deleted on chromosome 10 (PTEN) upregulation and reversal of the inhibitory effect of miR-218 upregulation on HCC proliferation. Our results indicate that miR-218 modulates HCC development, and this effect may be through RET and PTEN.
Literature
1.
go back to reference Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010;27:2893–917.CrossRef Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008. Int J Cancer. 2010;27:2893–917.CrossRef
2.
go back to reference Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.CrossRefPubMed
3.
go back to reference Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–69.CrossRefPubMed Rahbari NN, Mehrabi A, Mollberg NM, Muller SA, Koch M, Buchler MW, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg. 2011;253:453–69.CrossRefPubMed
4.
go back to reference Worns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302–309.CrossRefPubMed Worns MA, Galle PR. Future perspectives in hepatocellular carcinoma. Dig Liver Dis. 2010;42 Suppl 3:S302–309.CrossRefPubMed
5.
go back to reference Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, Frilling A: Liver transplantation for neuroendocrine tumour liver metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014 Fan ST, Le Treut YP, Mazzaferro V, Burroughs AK, Olausson M, Breitenstein S, Frilling A: Liver transplantation for neuroendocrine tumour liver metastases. HPB : the official journal of the International Hepato Pancreato Biliary Association 2014
6.
go back to reference Page AJ, Weiss MJ, Pawlik TM: Surgical management of noncolorectal cancer liver metastases. Cancer 2014. Page AJ, Weiss MJ, Pawlik TM: Surgical management of noncolorectal cancer liver metastases. Cancer 2014.
7.
go back to reference Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15:563–8.CrossRefPubMed Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev. 2005;15:563–8.CrossRefPubMed
9.
go back to reference Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310:1817–21.CrossRefPubMed Farh KK, Grimson A, Jan C, Lewis BP, Johnston WK, Lim LP, et al. The widespread impact of mammalian microRNAs on mRNA repression and evolution. Science. 2005;310:1817–21.CrossRefPubMed
10.
11.
go back to reference Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113:6207–33.CrossRefPubMed Dong H, Lei J, Ding L, Wen Y, Ju H, Zhang X. MicroRNA: function, detection, and bioanalysis. Chem Rev. 2013;113:6207–33.CrossRefPubMed
12.
go back to reference Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 1845;2014:255–65. Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM. Regulation of microRNAs in cancer metastasis. Biochim Biophys Acta. 1845;2014:255–65.
13.
go back to reference Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.CrossRefPubMed Huang J, Zhang SY, Gao YM, Liu YF, Liu YB, Zhao ZG, et al. MicroRNAs as oncogenes or tumour suppressors in oesophageal cancer: potential biomarkers and therapeutic targets. Cell Prolif. 2014;47:277–86.CrossRefPubMed
15.
go back to reference Seton-Rogers S. Tumour suppressors: hippo promotes microRNA processing. Nat Rev Cancer. 2014;14:216–7.CrossRefPubMed Seton-Rogers S. Tumour suppressors: hippo promotes microRNA processing. Nat Rev Cancer. 2014;14:216–7.CrossRefPubMed
16.
go back to reference Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013;73:473–7.CrossRefPubMed Baer C, Claus R, Plass C. Genome-wide epigenetic regulation of miRNAs in cancer. Cancer Res. 2013;73:473–7.CrossRefPubMed
17.
go back to reference Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20:6906–11.CrossRefPubMedPubMedCentral Xin SY, Feng XS, Zhou LQ, Sun JJ, Gao XL, Yao GL. Reduced expression of circulating microRNA-218 in gastric cancer and correlation with tumor invasion and prognosis. World J Gastroenterol. 2014;20:6906–11.CrossRefPubMedPubMedCentral
18.
go back to reference Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.CrossRefPubMed Uesugi A, Kozaki K, Tsuruta T, Furuta M, Morita K, Imoto I, et al. The tumor suppressive microRNA miR-218 targets the mTOR component Rictor and inhibits AKT phosphorylation in oral cancer. Cancer Res. 2011;71:5765–78.CrossRefPubMed
19.
go back to reference He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2012;18:1491–8.PubMedCentral He X, Dong Y, Wu CW, Zhao Z, Ng SS, Chan FK, et al. MicroRNA-218 inhibits cell cycle progression and promotes apoptosis in colon cancer by downregulating BMI1 polycomb ring finger oncogene. Mol Med. 2012;18:1491–8.PubMedCentral
20.
21.
go back to reference Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 1996;381:785–9.CrossRefPubMed Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature. 1996;381:785–9.CrossRefPubMed
22.
go back to reference Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–81.CrossRefPubMed Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, et al. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012;18:378–81.CrossRefPubMed
23.
go back to reference Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–4.CrossRefPubMedPubMedCentral Lipson D, Capelletti M, Yelensky R, Otto G, Parker A, Jarosz M, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med. 2012;18:382–4.CrossRefPubMedPubMedCentral
24.
go back to reference Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96:143–8.CrossRefPubMed Kodama Y, Asai N, Kawai K, Jijiwa M, Murakumo Y, Ichihara M, et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci. 2005;96:143–8.CrossRefPubMed
25.
go back to reference Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001;12:361–73.CrossRefPubMed Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev. 2001;12:361–73.CrossRefPubMed
26.
go back to reference Yin L, Puliti A, Bonora E, Evangelisti C, Conti V, Tong WM, et al. C620r mutation of the murine RET proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes. Int J Cancer. 2007;121:292–300.CrossRefPubMed Yin L, Puliti A, Bonora E, Evangelisti C, Conti V, Tong WM, et al. C620r mutation of the murine RET proto-oncogene: loss of function effect in homozygotes and possible gain of function effect in heterozygotes. Int J Cancer. 2007;121:292–300.CrossRefPubMed
27.
go back to reference Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.CrossRefPubMed Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006;7:606–19.CrossRefPubMed
28.
go back to reference Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005;10:479–98.PubMed Janus A, Robak T, Smolewski P. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy. Cell Mol Biol Lett. 2005;10:479–98.PubMed
29.
go back to reference Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929–40.CrossRefPubMed Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, et al. Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer. 2003;97:1929–40.CrossRefPubMed
30.
go back to reference Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007;28:879–87.CrossRefPubMed Cao LQ, Chen XL, Wang Q, Huang XH, Zhen MC, Zhang LJ, et al. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol Sin. 2007;28:879–87.CrossRefPubMed
31.
go back to reference Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.CrossRefPubMedPubMedCentral Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133:647–58.CrossRefPubMedPubMedCentral
32.
go back to reference Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, et al. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 2010;23:1593–600.PubMed Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, et al. PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 2010;23:1593–600.PubMed
33.
go back to reference Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis c virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed Varnholt H, Drebber U, Schulze F, Wedemeyer I, Schirmacher P, Dienes HP, et al. MicroRNA gene expression profile of hepatitis c virus-associated hepatocellular carcinoma. Hepatology. 2008;47:1223–32.CrossRefPubMed
34.
go back to reference Zhang LS, Liang WB, Gao LB, Li HY, Li LJ, Chen PY, et al. Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 2012;31:761–5.CrossRefPubMed Zhang LS, Liang WB, Gao LB, Li HY, Li LJ, Chen PY, et al. Association between pri-miR-218 polymorphism and risk of hepatocellular carcinoma in a Han Chinese population. DNA Cell Biol. 2012;31:761–5.CrossRefPubMed
35.
Metadata
Title
Overexpression of miR-218 inhibits hepatocellular carcinoma cell growth through RET
Authors
Chengjun Sui
Feng Xu
Weifeng Shen
Li Geng
Feng Xie
Binghua Dai
Jiongjiong Lu
Minfeng Zhang
Jiamei Yang
Publication date
01-03-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 3/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2679-1

Other articles of this Issue 3/2015

Tumor Biology 3/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine